Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Adobe, Lowers Price Target to $665

Barclays analyst Saket Kalia maintains Adobe (NASDAQ:ADBE) with a Overweight and lowers the price target from $740 to $665.

byBenzinga Newsdesk

December 17, 2021

1 minute read

Barclays analyst Saket Kalia maintains Adobe (NASDAQ:ADBE) with a Overweight and lowers the price target from $740 to $665.

Guggenheim Initiates Coverage On Fortinet with Neutral Rating

By Benzinga Newsdesk

Today, 4:11 AM

Guggenheim analyst Raymond McDonough initiates coverage on Fortinet (NASDAQ:FTNT) with a Neutral rating.

FTNT

FDA
News

Deciphera Announces Positive CHMP Opinion For QINLOCK For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor

By Benzinga Newsdesk

Today, 4:11 AM

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Medicines

DCPH

Microsoft Names CEO Satya Nadella As Board Chair

By Rachit Vats

Today, 4:11 AM

Microsoft Corp (NASDAQ: MSFT) said Wednesday CEO Satya Nadella will take over the role of company chair.

AAPL

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet

By Lisa Levin

Today, 4:11 AM

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping 100 points on Wednesday.

APPS

Barclays Maintains Overweight on Adobe, Lowers Price Target to $665

Related Posts

Guggenheim Initiates Coverage On Fortinet with Neutral Rating

Deciphera Announces Positive CHMP Opinion For QINLOCK For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor

Microsoft Names CEO Satya Nadella As Board Chair

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet